Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin succinate suspension in children and adolescents with neurogenic detrusor overactivity
NL-OMON37388Phase 3Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of solifenacin in detrusor hyperreflexia (DH) and overactive bladder (OAB), sponsored by Astellas Pharma. Primary endpoint: Change from baseline in maximum cystometric capacity. Planned start Jan 2012; status: withdrawn.
02
Drugs
solifenacin
03
Conditions
detrusor hyperreflexia (DH)overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON37388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37388.